Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis

NCT06982352 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis (AD)
Psoriasis (PsO)

Interventions

DRUG: LPX-TI641
DRUG: Placebo

Sponsor

LAPIX Therapeutics Inc.